Claims for Patent: 10,265,288

Summary for Patent: 10,265,288

Title:	Methods and compositions for the treatment of proliferative disorders
Abstract:	The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.
Inventor(s):	Lu; Kun Ping (Newton, MA), Wei; Shuo (Chestnut Hill, MA), Zhou; Xiao Zhen (Newton, MA)
Assignee:	Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Application Number:	14/334,052
Patent Claims:	1. A method of treating a cancer or leukemia in a subject with the cancer or leukemia, respectively, said method comprising: (a) performing an assay to identify the subject as having an elevated level of Pin1 in the cells of the cancer relative to non-cancerous cells of the same tissue type: and (b) administering to said subject a pharmaceutical composition comprising: (i) an effective amount of a retinoic acid compound, and (ii) one or more additional therapeutic agents, wherein the retinoic acid compound is administered to the subject as the sole Pin1 inhibitor and in an amount that reduces Pin1 activity in the cells of the cancer or leukemia by 30% or more relative to a subject not administered the retinoic acid compound, and wherein said retinoic acid compound, but not said one or more additional therapeutic agents, is formulated for controlled or extended release. 2. The method of claim 1, wherein the rate of release of said retinoic acid compound exceeds the rate of metabolism of said retinoic acid compound. 3. The method of claim 1, wherein said retinoic acid compound is released at period intervals. 4. The method of claim 1, wherein said pharmaceutical composition is formulated as a single unit tablet, multiple unit tablet, capsule, oil solution, suspension, emulsion, microcapsule, microsphere, nanoparticle, or patch. 5. The method of claim 1, wherein said pharmaceutical composition comprises one or more liposomes comprising said retinoic acid compound. 6. The method of claim 1, wherein said one or more additional therapeutic agents comprises one or more anti-proliferative agents. 7. The method of claim 1, wherein said pharmaceutical composition is formulated such that the release of said retinoic acid compound and said one or more additional therapeutic agents is simultaneous. 8. The method of claim 1, wherein said pharmaceutical composition is formulated such that said retinoic acid compound is released prior to said one or more additional therapeutic agents. 9. The method of claim 1, wherein said pharmaceutical composition is formulated such that said retinoic acid compound is released after said one or more additional therapeutic agents. 10. The method of claim 1, wherein said retinoic acid compound is all-trans retinoic acid. 11. The method of claim 1, wherein said cancer or leukemia is selected from the group consisting of: acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemi), Hodgkin's disease, non-Hodgkin's disease, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma. 12. The method of claim 11, wherein said cancer or leukemia is breast cancer. 13. The method of claim 1, wherein said pharmaceutical composition and said one or more therapeutic agents are administered separately or in a single formulation. 14. A method of treating a cancer or leukemia in a subject with the cancer or leukemia, respectively, said method comprising: (a) performing an assay to identify the subject as having an elevated level of Pin1 in the cells of the cancer relative to non-cancerous cells of the same tissue type: and administering to said subject a pharmaceutical composition comprising: (i) an effective amount of a retinoic acid compound, and (ii) a second therapeutic agent selected from the group consisting of a microtubule inhibitor, a topoisomerase inhibitor, a platin, an alkylating agent, an anti-metabolite, an AKT antagonist, a cyclin D1 antagonist, a HER2 antagonist, an NF-kB antagonist, a Plk antagonist, a Raf-1 antagonist, a Stat3 antagonist, and an ISIS-STAT antagonist; wherein the retinoic acid compound is administered to the subject as the sole Pin1 inhibitor and in an amount that reduces Pin1 activity in the cells of the cancer or leukemia by 30% or more relative to a subject not administered the retinoic acid compound, and wherein said pharmaceutical composition is formulated for controlled or extended release. 15. A method of treating a cancer or leukemia in a subject with the cancer or leukemia, respectively, said method comprising: (a) performing an assay to identify the subject as having an elevated level of Pin1 in the cells of the cancer relative to non-cancerous cells of the same tissue type: and (b) administering to said subject having elevated levels of Pin1 activity a pharmaceutical composition comprising: (i) an effective amount of a retinoic acid compound, and (ii) a second therapeutic agent selected from the group consisting of MK-2206, ON 013105, Herceptin, RTA 402, B12536, Sorafenib, ISIS-STAT3Rx, paclitaxel, gemcitabine, doxorubicin, vinblastine, etoposide, 5-fluorouracil, carboplatin, altretamine, aminoglutethimide, amsacrine, anastrozole, azacitidine, bleomycin, busulfan, carmustine, chlorambucil, 2-chlorodeoxyadenosine, cisplatin, colchicine, cyclophosphamide, cytarabine, cytoxan, dacarbazine, dactinomycin, daunorubicin, docetaxel, estramustine phosphate, floxuridine, fludarabine, gentuzumab, hexamethylmelamine, hydroxyurea, ifosfamide, imatinib, interferon, irinotecan, lomustine, mechlorethamine, melphalen, 6-mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, pentostatin, procarbazine, rituximab, streptozocin, tamoxifen, temozolomide, teniposide, 6-thioguanine, topotecan, trastuzumab, vincristine, vindesine, and vinorelbine; wherein the retinoic acid compound is administered as the sole Pin1 inhibitor and in an amount that reduces Pin1 activity in the cells of the cancer or leukemia by 30% or more relative to a subject not administered the retinoic acid compound, and wherein said pharmaceutical composition is formulated for controlled or extended release. 16. The method of claim 1, wherein said retinoic acid is administered in an amount sufficient to reduce the Pin1 activity in the cells of said cancer by 50% or more relative to a subject not administered said retinoic acid compound. 17. The method of claim 16, wherein said retinoic acid is administered in an amount sufficient to reduce the Pin1 activity in the cells of said cancer by 90% or more relative to a subject not administered said retinoic acid compound. 18. The method of claim 14, wherein said retinoic acid compound is administered in an amount sufficient to reduce the Pin1 activity in the cells of said cancer by 50% or more relative to a subject not administered said retinoic acid compound. 19. The method of claim 15, wherein said retinoic acid compound is administered in an amount sufficient to reduce the Pin1 activity in the cells of said cancer by 50% or more relative to a subject not administered said retinoic acid compound.

Details for Patent 10,265,288

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-03-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-03-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-03-14